Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Monograph series

Reproductive-axis peptides

Kisspeptin and gonadotropin-releasing hormone and their analogues.

All seriesIncretin receptor agonistsAmylin analoguesCombinations and unimolecular co-agonistsGrowth-hormone axisRepair and regenerationNeuroactive peptidesImmune modulatorsMitochondrial and metabolic cofactorsMelanocortin receptor agonistsReproductive-axis peptides

Monographs in this series

2 documents
  • Gonadorelin
    CEI-MN-051Reproductive-axis peptidesApproved2 assessed outcomesversion 3.2

    Gonadorelin stimulates pituitary release of luteinising hormone and follicle-stimulating hormone. Its pharmacology is dominated by a pattern dependence that is unusual and clinically decisive: pulsatile administration stimulates…

    Moderate18 Jan 2024
  • Kisspeptin-10
    CEI-MN-050Reproductive-axis peptidesUnapproved, research supply3 assessed outcomesversion 2.2

    Kisspeptin acts on KISS1 receptors on hypothalamic gonadotropin-releasing hormone neurons to stimulate GnRH secretion, and thereby luteinising hormone and follicle-stimulating hormone release. Because it acts upstream of GnRH it…

    Low11 Jun 2025
Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.